Evidence map›Paper›PMID 32020857›Full record

ArticleBMC complementary medicine and therapies2020

Neuroprotective effects of Danshensu on rotenone-induced Parkinson's disease models in vitro and in vivo.

Tian Wang, Cuiting Li, Bing Han, Zhenhua Wang, Xiaoyu Meng, Leiming Zhang, Jie He, Fenghua Fu

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tian WangSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Qingquan Road 30#, Yantai, Shandong, 264005, People's Republic of China.
Cuiting LiSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Qingquan Road 30#, Yantai, Shandong, 264005, People's Republic of China.
Bing HanCenter of Mitochondria and Healthy Aging, School of Life Science, Yantai University, Qingquan Road 30#, Yantai, Shandong, 264005, People's Republic of China.
Zhenhua WangCenter of Mitochondria and Healthy Aging, School of Life Science, Yantai University, Qingquan Road 30#, Yantai, Shandong, 264005, People's Republic of China.
Xiaoyu MengSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Qingquan Road 30#, Yantai, Shandong, 264005, People's Republic of China.
Leiming ZhangSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Qingquan Road 30#, Yantai, Shandong, 264005, People's Republic of China.
Jie HeCenter of Mitochondria and Healthy Aging, School of Life Science, Yantai University, Qingquan Road 30#, Yantai, Shandong, 264005, People's Republic of China.
Fenghua FuSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Qingquan Road 30#, Yantai, Shandong, 264005, People's Republic of China. fufenghua@sohu.com.ORCID http://orcid.org/0000-0002-5659-013X
Yantai University · CN

Funding

Natural Science Foundation of Shandong Province ZR2015HM034
6 · The paper itself

Abstract

backgroundDanshensu is an active constituent in the extracts of Danshen which is a traditional Chinese medical herb. Rotenone inhibits complex I of the mitochondrial electron transport chain in dopaminergic neurons leading to glutathione (GSH) level reduction and oxidative stress. The aim of this study is to investigate neuroprotective effects of Danshensu on rotenone-induced Parkinson's disease (PD) in vitro and in vivo.

methodsIn vitro, SH-SY5Y human neuroblastoma cell line was pretreated with Danshensu and challenged with rotenone. Then the reactive oxygen species (ROS) production was assayed. In vivo, male C57BL/6 mice were intragastrically administered with Danshensu (15, 30, or 60 mg/kg), followed by oral administration with rotenone at a dose of 30 mg/kg. Pole and rotarod tests were carried out at 28 d to observe the effects of Danshensu on PD.

resultsDanshensu repressed ROS generation and therefore attenuated the rotenone-induced injury in SH-SY5Y cells. Danshensu improved motor dysfunction induced by rotenone, accompanied with reducing MDA content and increasing GSH level in striatum. Danshensu increased the number of TH positive neurons, the expression of TH and the dopamine contents. The expressions of p-PI3K, p-AKT, Nrf2, hemeoxygenase (HO-1), glutathione cysteine ligase regulatory subunit (GCLC), glutathione cysteine ligase modulatory subunit (GCLM) were significantly increased and the expression of Keap1 was decreased in Danshensu groups.

conclusionsThe neuroprotective effects of Danshensu on rotenone-induced PD are attributed to the anti-oxidative properties by activating PI3K/AKT/Nrf2 pathway and increasing Nrf2-induced expression of HO-1, GCLC, and GCLM, at least in part.

Indexed as

AnimalsBlotting, WesternCell Line, TumorDisease Models, AnimalFlow CytometryHumansLactatesMaleMedicine, Chinese TraditionalMiceMice, Inbred C57BLNeuroprotective AgentsParkinson DiseaseRotarod Performance TestRotenone3,4-dihydroxyphenyllactic acidLactatesNeuroprotective AgentsRotenoneDanshensuGlutathioneParkinson’s diseaseRotenone

Identifiers

PMID32020857
PMCPMC7076814
OpenAlexW3013065729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.